Abstract
The development of an antitumor vaccine based on autologous dendritic cells (DCs) for bladder cancer treatment is extremely relevant today due to the proven high immunological potency of this type of tumor. Vaccination with DCs-based drugs as a monotherapy or in combination with other methods of treatment has shown to be effective in cancer therapy. The vaccine administration is considered to be safe, the associated side effects are insignificant and can be characterized as undesirable phenomena of 1st or 2nd degree. There are a number of issues that arise while creating DCs vaccines that need to be carefully resolved. Among them, the problem of selecting potential targets for the vaccine treatment, the ways to enhance the potency of the vaccine, and the selection of technology for obtaining a sufficient number of functional DCs should be specifically mentioned. The review focuses on the use of autoantigen or alloantibody material for the activation of DCs, and the results of experimental and clinical studies of DCs vaccines in bladder cancer.
Highlights
Разработка противоопухолевой вакцины для терапии рака мочевого пузыря на основе аутологичных дендритных клеток (ДК) на сегодняшний день весьма актуальна в связи с доказанной высокой иммуногенностью этого вида опухолей
The development of an antitumor vaccine based on autologous dendritic cells (DCs) for bladder cancer treatment is extremely relevant today due to the proven high immunological potency of this type of tumor
Vaccination with DCs-based drugs as a monotherapy or in combination with other methods of treatment has shown to be effective in cancer therapy
Summary
Разработка противоопухолевой вакцины для терапии рака мочевого пузыря на основе аутологичных дендритных клеток (ДК) на сегодняшний день весьма актуальна в связи с доказанной высокой иммуногенностью этого вида опухолей. Ввиду восприимчивости опухоли к ИТ в литературе появляются сообщения об исследованиях, посвященных применению адоптивной ИТ с использованием аутологичных Т-лимфоцитов, а также разработке противоопухолевых вакцин РМП, в том числе на основе дендритных клеток (ДК) [15,16,17].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
